Long-Term Outcomes of Active Surveillance for Prostate Cancer - Interview with Sigrid Carlsson

June 12, 2018

Sigrid Carlsson, MD talks with Alicia Morgans, MD about long-term outcomes of active surveillance for prostate cancer, a 17-year experience with active surveillance at the Memorial Sloan Kettering Cancer Center.  A study which Carlsson was a co-author on and was presented at the most recent American Urological Association meeting (AUA2018).  This was a retrospective analysis of all patients managed with active surveillance from 2000-2017, a longitudinal follow-up and one of the longest-running followups in the world. Included in this discussion are primary findings and treatment-free survival rates. 

Sigrid Carlsson, MD, Ph.D., MPH is the assistant attending epidemiologist at the Memorial Sloan Kettering Cancer Center. Dr. Carlsson’s research is focused on screening and early detection of prostate cancer. She is an investigator in the world’s largest randomized study of screening for prostate cancer, the European Randomized Study of Screening for Prostate Cancer. Dr. Carlsson’s research aims at finding a better balance between the harms and benefits of prostate-specific antigen (PSA) screening, through the use of multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers, and magnetic resonance imaging.

Alicia Morgans, MD, MPH

Study Discussed in this Conversation: 
Long-Term Outcomes of Active Surveillance for Prostate Cancer - Memorial Sloan Kettering Cancer Center Experience